急性脑梗死超早期静脉应用尿激酶溶栓疗效临床分析

【摘要】目的分析急性脑梗死患者超早期静脉应用尿激酶溶栓疗效。方法将对符合人选标准的80例患者随机分为溶栓组和对照组，溶栓组应用尿激酶（UK）静脉滴注；对照组应用肠溶阿司匹林，联合应用改善循环药物。分别于治疗前及治疗后4周，采用中国脑卒中患者临床神经功能缺损程度评分标准（1995）（CSS）对患者进行评定。结果治疗前溶栓组的CSS评分与对照组比较差异均无统计学意义（P〉0．05），而治疗后两组的CSS评分差异均有统计学意义（P〈0．01）；两组疗效差异有统计学意义（P〈0．05）。结论急性脑梗死患者用尿激酶超早期静脉溶栓治疗疗效较好且安全可靠。

Clinic analysis for ultra-early intravenous thrombolysis with Urokinase in acute cerebral infraction

Objective To analyze the efficacy of ultra-early intravenous thrombolysis with urokinase in acute cerebral Infractions. Methods Eighty qualified patients were randomly divided into the thrombolysis group and the control group. The thrombolysis group was given Urokinase intravenously, while the control group was treated with aspirin, combined with drugs improved circulation. Paitents＂ degree of neurological deficit were evaluated by China Stroke Scale（CSS） before treatment and four weeks after thrombolysis. Results CSS scores of the thrombolysis group and con- trol group were not significantly different before treatment （P 〉 0.05） while CSS scores after treatment of two groups were significantly different （P 〈 0.01）. The curative effect between two groups were statistically significant （P 〈 0.05）. Conclusion The therapy of ultra-early intravenous thrombolysis with Urokinase is effective, safe and reliable in acute cerebral infraction.